Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in patients with resected stage I to III non-small-cell lung cancer (NSCLC) harbouring an activating EGFR mutation.
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation / Occhipinti, M.; Ferrara, R.; Imbimbo, M.; Simeon, V.; Fiscon, G.; Marchal, C.; Skoetz, N.; Viscardi, G.. - In: COCHRANE LIBRARY. - ISSN 1465-1858. - 2022:3(2022), pp. 1-13. [10.1002/14651858.CD015140]
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation
Occhipinti M.Primo
;Fiscon G.;
2022
Abstract
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in patients with resected stage I to III non-small-cell lung cancer (NSCLC) harbouring an activating EGFR mutation.| File | Dimensione | Formato | |
|---|---|---|---|
|
Occhipinti_Adjuvant-epidermal_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
178.74 kB
Formato
Adobe PDF
|
178.74 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
